新マイナー・トランキライザー "clorazepate dipotassium(Mendon)"の心身症, 神経症, うつ状態等に対する二重盲検法による薬効検定

概要

論文の詳細を見る
In cooperative research at 10 institutes in the fields of internal medicine, psychiatry and ophthalmology, Mendon (Clorazepate dipotassium) was studied clinically regarding its efficacy, safety and most effective dosage for psychsomatic diseases, neurosis and depressive states by using the double blind method in comparison with diazepam and placebo. The number of patients totaled 181. Among them, 143 completed the trial period, 165 received the physician's judgement and 16 were dropped out frorn the evaluation without physician's judgement due to such reasons as, patients visiting the hospital only once, etc. 1) Physicians' judgement of overall therapeutic response showed statistically significant differences in favor of Mendon over placebo but no significant difference when compared to diazepam. 2) In proportion to the period of therapy, Mendon showed a tendency of a rising curve of improvernent in symptorns, which was clearer than diazepam, according to the Hamilton A.R.S. and PNRS-S evaluation scales. 3) After studying side effects and laboratory findings, investigators considered that Mendon was a drug of high safety. 4) From the results of these studies, 9mg of Mendon per day is considered to be the optimum effective dosage. However, it is recommended that the dosage is tailorcd to the need of each patient with due consideration to his response as well as side effects.
日本心身医学会の論文
1975-08-01